Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.92 |
| ▸ | ESR1 | P03372 | 4/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1344 | 1.00 | TDP1 (0.92) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL3710821 | 1.00 | TDP1 (0.92) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL1747083 | 1.00 | TDP1 (0.92) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL3931585 | 1.00 | TDP1 (0.92) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL4718125 | 1.00 | TDP1 (0.92) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL236600 | 1.00 | TDP1 (0.92) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL5968399 | 1.00 | TDP1 (0.92) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL201704 | 1.00 | TDP1 (0.92) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL22558063 | 1.00 | TDP1 (0.92) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL722872 | 1.00 | TDP1 (0.92) | TDP1CYP3A4ESR1ESR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12604663-B2 | Double-capped micromolecule electron donor material and preparation and application thereof | CHONGQING INSTITUTE OF GREEN AND INTELLIGENT TECHNOLOGY, CHINESE ACADEMY OF SCIENCES (CN) | 2026-04-14 | — | — | US | claimed |
| US-20230397496-A1 | DOUBLE-CAPPED MICROMOLECULE ELECTRON DONOR MATERIAL AND PREPARATION AND APPLICATION THEREOF | CHONGQING INSTITUTE OF GREEN AND INTELLIGENT TECHNOLOGY, CHINESE ACADEMY OF SCIENCES (CN) | 2023-12-07 | — | — | US | claimed |
| US-12604663-B2 | Double-capped micromolecule electron donor material and preparation and application thereof | CHONGQING INSTITUTE OF GREEN AND INTELLIGENT TECHNOLOGY, CHINESE ACADEMY OF SCIENCES (CN) | 2026-04-14 | — | — | US | disclosed |
| US-20240182477-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2024-06-06 | — | — | US | disclosed |
| CN-118063493-A | Near infrared two-region AIE compound and preparation method and application thereof | 南方医科大学南方医院 | 2024-05-24 | — | — | CN | disclosed |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11884675-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-01-30 | — | — | US | disclosed |
| CN-109790136-B | Furan cross-linking group-containing polymer and application thereof | 广州华睿光电材料有限公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-117384256-A | Lumbricus polypeptide, preparation method and application thereof | 福建中医药大学 | 2024-01-12 | — | — | CN | disclosed |
| EP-3560917-B1 | POLYMER CONTAINING FURAN CROSSLINKING GROUP AND USE THEREOF | GUANGZHOU CHINARAY OPTOELECTRONIC MAT LTD (CN) | 2023-12-20 | — | — | EP | disclosed |
| US-20230397496-A1 | DOUBLE-CAPPED MICROMOLECULE ELECTRON DONOR MATERIAL AND PREPARATION AND APPLICATION THEREOF | CHONGQING INSTITUTE OF GREEN AND INTELLIGENT TECHNOLOGY, CHINESE ACADEMY OF SCIENCES (CN) | 2023-12-07 | — | — | US | disclosed |
| EP-1054870-A1 | HETEROCYCLIC TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2000-11-29 | — | — | EP | disclosed |
| US-6063801-A | Heterocyclic topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2000-05-16 | — | — | US | disclosed |
| WO-1999041241-A1 | HETEROCYCLIC TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1999-08-19 | — | — | WO | disclosed |
| US-5494666-A | BETA-LACTAMASE INHIBITORS, ANTIBACTERIALS | HOFFMANN-LA ROCHE INC. (US) | 1996-02-27 | — | — | US | disclosed |
| US-5464617-A | 1H-2,6a-diazacyclobut(cd)indene-6-carboxylic acid derivatives, antibiotics | HOFFMANN-LA ROCHE INC. (US) | 1995-11-07 | — | — | US | disclosed |
| EP-0671401-A1 | Beta lactames | F. HOFFMANN-LA ROCHE AG (CH) | 1995-09-13 | — | — | EP | disclosed |
| EP-0109044-B1 | PENEMS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCESS FOR PREPARING THEM | SCHERING CORPORATION (US) | 1986-10-15 | — | — | EP | disclosed |
| US-4540579-A | 2-[(R) Amino acid alkyl]penems | SCHERING CORPORATION (US) | 1985-09-10 | — | — | US | disclosed |
| EP-0109044-A1 | Penems, pharmaceutical compositions containing them, process for preparing them | SCHERING CORPORATION (US) | 1984-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230397496-A1 | DOUBLE-CAPPED MICROMOLECULE ELECTRON DONOR MATERIAL AND PREPARATION AND APPLICATION THEREOF | STOML2, NME4, STOM | TDP1 2054/4885CYP3A4 4226/4885ESR1 1333/4885 |
| US-20240182477-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | TDP1 697/4885CYP3A4 1273/4885ESR1 755/4885 |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | TDP1 697/4885CYP3A4 1273/4885ESR1 755/4885 |
| US-12604663-B2 | Double-capped micromolecule electron donor material and preparation and application thereof | PRKD1, CTNND1, CDH1 | TDP1 2460/4885CYP3A4 2831/4885ESR1 370/4885 |
| US-11884675-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | TDP1 697/4885CYP3A4 1273/4885ESR1 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.